News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Associatio...

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Ann

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalat...

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation P

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potentia...

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust...

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targ

Teva Reports First Quarter 2022 Financial Results

Teva Reports First Quarter 2022 Financial Results

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, ...

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Feature stories

Discover the world of Teva

Teva Joins Digital Health for Equitable Health Alliance (DHEH)

Teva Joins Digital Health for Equitable Health Alliance (DHEH)

Making Connections for the Health of People and Our World: Teva's 2021 ESG Progress Report

Making Connections for the Health of People and Our World: Teva's 2021 ESG Progress Report

Healthy Returns: How Teva is Making Innovative Use of AI and Advanced Analytics

Healthy Returns: How Teva is Making Innovative Use of AI and Advanced Analytics

Teva Expands Partnership to Bring Critical Medicines to Children Living with Cancer

Teva Expands Partnership to Bring Critical Medicines to Children Living with Cancer

Paving paths through mentorship: Ana and Kirsten

Paving paths through mentorship: Ana and Kirsten

Paving paths through mentorship: Debbie and Shosh

Paving paths through mentorship: Debbie and Shosh

Paving paths through mentorship: Tricia and Oindrila

Paving paths through mentorship: Tricia and Oindrila

Introducing Teva USA’s 2022 HBA Rising Stars & Luminary

Introducing Teva USA’s 2022 HBA Rising Stars & Luminary

Saving Water and Sustaining the Environment

Saving Water and Sustaining the Environment

All the Latest on LinkedIn

May 18, 2022

Biosimilar medicines are potentially less expensive than original biologics, whilst having the same effectiveness. Meet Cory Wohlbach, who is responsible for steering Teva’s new biosimilar products through the regulatory approval process. Here he explains how biosimilars have the potential to reduc...

Read more

May 17, 2022

Meet Samuel Frere and Elena Lapkina Gendler, scientists who work in the non-clinical (early stage) research lab in Netanya, Israel. Their work allows their group to test the effect of Teva drugs on gene expression and on cellular function. While they took very different paths to get there, both...

Read more

May 16, 2022

Last week we hosted Association for Accessible Medicines (AAM) at our Parsippany, NJ HQ as a part of their Generics Are the Solution tour. On this tour AAM is on the road visiting with generic and biosimilar drugmakers across the country to share the work the association is doing as well as learn mo...

Read more

May 16, 2022

At Teva, we know that providing medicines is an important job—and conducting business ethically and responsibly is non-negotiable. In 2021, we trained 20,000+ employees on ethics (99.6% of those assigned), published three new position statements on patient safety, responsible supply chain and risk m...

Read more

May 15, 2022

When most of us think about becoming parents, we picture sunlit afternoons chasing our toddlers through the park, birthday parties, vacations, and school sports days. We often don't envision how difficult parenting can be when coping with the pain, fatigue, hospital appointments, and diagnoses that...

Read more

May 12, 2022

What does family mean to you? For many of us, no words could encompass the emotional, developmental, and spiritual importance of family life. Family is about love. It's about understanding, hope, comfort, advice, and encouragement. We treasure the people on our home team through the good times and t...

Read more

May 11, 2022

In collaboration with Morehouse School of Medicine, we conducted a survey on the State of Access to Healthcare in America. Our findings show that we must take action to address #healthcare barriers within our communities. Read our survey findings here to learn more here: https://bit.ly/3l009Dv #Pat...

Read more

May 11, 2022

Yesterday we had the pleasure of hosting the Teva satellite event "Challenges & Opportunities in CNS Drug Discovery" at the 2022 Biomed conference. Thank you to all the participants, the room was full of unique energy. We learned about multidisciplinary efforts to advance this complex field such as...

Read more

May 09, 2022

Further unlocking the value of critical medicines with biosimilars is an important frontier in drug development. It offers patients safe and effective treatment options through more affordable alternatives to branded biological products that have lost their exclusivity rights.  Accelerating patient...

Read more

May 05, 2022

Supporting patient lives and healthcare systems: we’re using Artificial Intelligence (AI) and advanced analytics to improve the drug development process and help provide medicines for patients with various conditions such as schizophrenia, depression, Parkinson’s and Chronic Obstructive Pulmonary Di...

Read more

Media Resources

Media Inquiries

Contact our corporate communications.

Learn more Media Inquiries

Media Kit

Files and resources for media use only

Download Teva Media Kit Media Kit

Financial Reports

View Teva financial news on our global website.

Learn more Financial Reports

Connect with us

Teva Social Media Guidelines.

Learn more Connect with us